Diana Estefanía Cadenas García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diana Estefanía Cadenas García has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Rosalaura Virginia Villarreal-González
Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Servicio de Oncología, Centro Universitario Contra el Cáncer. Facultad de Medicina, Monterrey, Nuevo León, México
3 shared publications - Oscar Vidal-Gutiérrez
Oncology Service, University Hospital “Dr José Eleuterio González”, Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico
2 shared publications - Alira Fraga Olvera
Hospital Amerimed Playa del Carmen, Quintana Roo / Medical Concierce México
1 shared publication - Anabel Ávila Lara
Hospital ISSSTE Tláhuac, Ciudad de México
1 shared publication - Angélica Delgado Bañuelos
Instituto Mexicano del Seguro Social, Hospital General Regional No. 58, Servicio de Alergia e Inmunología Clínica. León, Guanajuato, México
1 shared publication - Carlos Alberto Correa Serrano
Servicio de Alergia e inmunología Clínica Hospital Regional “Dr. Valentín Gómez Farías”, ISSSTE, Zapopan, Jalisco
1 shared publication
Latest Publications
- 4 August 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (8) , 1353-1357
Innovative strategies for cisplatin desensitization in hyperthermic intraperitoneal chemotherapy of ovarian cancer
We present a case of a 41-year-old female diagnosed with Granulosa Cell Tumor (GCT) EC IVB who developed a hypersensitivity reaction (HSR) to carboplatin during the sixth cycle of treatment and subsequently underwent successful intraperitoneal desensitization with cisplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). The patient experienced a severe HSR 30 min after carboplatin infusion, presenting with generalized rash, pruritus, nausea, chest pain, and dyspnea. The infusion was halted, and she was treated with intramuscular epinephrine (0.50 mg), intravenous chloropyramine (20 mg), and 250 mL saline, resolving symptoms. Platinum skin tests were subsequently performed and yielded negative results for carboplatin, cisplatin, and oxaliplatin. Following multidisciplinary consensus, cytoreductive surgery with HIPEC and intraperitoneal desensitization to cisplatin was planned. The patient had a peritoneal carcinomatosis index (PCI) of 17. Cytoreductive surgery included omentectomy, appendectomy, resection of mesenteric implants, diaphragmatic and parietal peritonectomy, in bloc hysterectomy, bilateral salpingo-oophorectomy, and pelvic peritonectomy, achieving a completeness of cytoreduction (CC-0). HIPEC was performed with cisplatin (100 mg/m²) at 42°C for 140 min. A desensitization protocol with intraperitoneal cisplatin (180 mg in 8 incremental steps over 140 min) was successfully completed without adverse reactions. Platinum-based chemotherapeutics are frequently associated with HSR, with increasing incidence upon repeated exposure. Intraperitoneal administration, as in HIPEC, may reduce systemic hypersensitivity risks. While prior cases have demonstrated safe HIPEC administration of cisplatin in patients with oxaliplatin-induced HSR, no documented cases exist of intraperitoneal drug desensitization in this context. Our case suggests that intraperitoneal desensitization with cisplatin may be a viable alternative for patients with systemic HSR to platinum agents. Further research is required to establish safety protocols, cross-reactivity risks, and efficacy outcomes for this approach.
- 4 August 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (8) , 1353-1357
Innovative strategies for cisplatin desensitization in hyperthermic intraperitoneal chemotherapy of ovarian cancer
We present a case of a 41-year-old female diagnosed with Granulosa Cell Tumor (GCT) EC IVB who developed a hypersensitivity reaction (HSR) to carboplatin during the sixth cycle of treatment and subsequently underwent successful intraperitoneal desensitization with cisplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). The patient experienced a severe HSR 30 min after carboplatin infusion, presenting with generalized rash, pruritus, nausea, chest pain, and dyspnea. The infusion was halted, and she was treated with intramuscular epinephrine (0.50 mg), intravenous chloropyramine (20 mg), and 250 mL saline, resolving symptoms. Platinum skin tests were subsequently performed and yielded negative results for carboplatin, cisplatin, and oxaliplatin. Following multidisciplinary consensus, cytoreductive surgery with HIPEC and intraperitoneal desensitization to cisplatin was planned. The patient had a peritoneal carcinomatosis index (PCI) of 17. Cytoreductive surgery included omentectomy, appendectomy, resection of mesenteric implants, diaphragmatic and parietal peritonectomy, in bloc hysterectomy, bilateral salpingo-oophorectomy, and pelvic peritonectomy, achieving a completeness of cytoreduction (CC-0). HIPEC was performed with cisplatin (100 mg/m²) at 42°C for 140 min. A desensitization protocol with intraperitoneal cisplatin (180 mg in 8 incremental steps over 140 min) was successfully completed without adverse reactions. Platinum-based chemotherapeutics are frequently associated with HSR, with increasing incidence upon repeated exposure. Intraperitoneal administration, as in HIPEC, may reduce systemic hypersensitivity risks. While prior cases have demonstrated safe HIPEC administration of cisplatin in patients with oxaliplatin-induced HSR, no documented cases exist of intraperitoneal drug desensitization in this context. Our case suggests that intraperitoneal desensitization with cisplatin may be a viable alternative for patients with systemic HSR to platinum agents. Further research is required to establish safety protocols, cross-reactivity risks, and efficacy outcomes for this approach.
- Open Access
- 31 March 2025
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 72 (1) , 52-71
Reacciones adversas por anticuerpos monoclonales en el tratamiento de enfermedades alérgicas. Posicionamiento de Grupo: Comité de Alergia a Medicamentos del Colegio Mexicano de Inmunología Clínica y Alergia (CMICA 2024-2025)
Antecedentes: Los anticuerpos monoclonales representan una opción de tratamiento en pacientes con enfermedades alérgicas, autoinmunes, oncológicas, entre otras. Su función consiste en inhibir las interacciones entre moléculas efectoras y sus receptores específicos. Sin embargo, el aumento de su prescripción ha provocado un incremento de las reacciones adversas a medicamentos. Este tipo de reacciones son respuestas dañinas e inesperadas a tratamientos terapéuticos. Se dividen en tipo A, relacionadas con la acción del medicamento y sus interacciones, y tipo B, asociadas con reacciones de hipersensibilidad. Objetivos: Se llevó a cabo una revisión bibliográfica de la prescripción de anticuerpos monoclonales en el tratamiento de enfermedades alérgicas, abordando la farmacocinética, farmacodinámica, posología, contraindicaciones y reacciones adversas. Metodología: La búsqueda de información se realizó en las principales bases de datos médicas, acerca de los anticuerpos monoclonales para el tratamiento de enfermedades alérgicas. La búsqueda se limitó a artículos originales, en idioma inglés y español, publicados entre 2014 y 2024. Se describe la actualización de la información relacionada con anticuerpos monoclonales para enfermedades alérgicas, incluyendo su mecanismo de acción, nombre comercial, indicaciones, posología, contraindicaciones y reacciones adversas. Conclusión: La recopilación de datos acerca de medicamentos biológicos es decisiva para la comprensión integral y actualizada de su prescripción clínica. Conocer las reacciones adversas mejora el entendimiento del diagnóstico y la calidad de la atención médica. Palabras clave: Anticuerpos monoclonales; Reacción adversa a medicamentos; Reacciones de hipersensibilidad; Farmacocinética; Farmacodinámica; Posología; Contraindicaciones; Reacciones adversas.
- 31 March 2025
- Published by Colegio Mexicano de Inmunologia Clinica y Alergia, A. C. in Revista Alergia México
- Vol. 72 (1) , 52-71
Open AccessReacciones adversas por anticuerpos monoclonales en el tratamiento de enfermedades alérgicas. Posicionamiento de Grupo: Comité de Alergia a Medicamentos del Colegio Mexicano de Inmunología Clínica y Alergia (CMICA 2024-2025)
Antecedentes: Los anticuerpos monoclonales representan una opción de tratamiento en pacientes con enfermedades alérgicas, autoinmunes, oncológicas, entre otras. Su función consiste en inhibir las interacciones entre moléculas efectoras y sus receptores específicos. Sin embargo, el aumento de su prescripción ha provocado un incremento de las reacciones adversas a medicamentos. Este tipo de reacciones son respuestas dañinas e inesperadas a tratamientos terapéuticos. Se dividen en tipo A, relacionadas con la acción del medicamento y sus interacciones, y tipo B, asociadas con reacciones de hipersensibilidad. Objetivos: Se llevó a cabo una revisión bibliográfica de la prescripción de anticuerpos monoclonales en el tratamiento de enfermedades alérgicas, abordando la farmacocinética, farmacodinámica, posología, contraindicaciones y reacciones adversas. Metodología: La búsqueda de información se realizó en las principales bases de datos médicas, acerca de los anticuerpos monoclonales para el tratamiento de enfermedades alérgicas. La búsqueda se limitó a artículos originales, en idioma inglés y español, publicados entre 2014 y 2024. Se describe la actualización de la información relacionada con anticuerpos monoclonales para enfermedades alérgicas, incluyendo su mecanismo de acción, nombre comercial, indicaciones, posología, contraindicaciones y reacciones adversas. Conclusión: La recopilación de datos acerca de medicamentos biológicos es decisiva para la comprensión integral y actualizada de su prescripción clínica. Conocer las reacciones adversas mejora el entendimiento del diagnóstico y la calidad de la atención médica. Palabras clave: Anticuerpos monoclonales; Reacción adversa a medicamentos; Reacciones de hipersensibilidad; Farmacocinética; Farmacodinámica; Posología; Contraindicaciones; Reacciones adversas.
- 28 August 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (6) , 955-964
Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy
Introduction: Taxanes and platinum are first-line treatments in gynecological tumors with high rates of hypersensitivity reactions (HSRs), leading to discontinuation of treatment. Desensitization involves induction of temporary tolerance to previously sensitized medications. The aims of this study are to describe HSRs to paclitaxel and carboplatin and evaluate the safety and effectiveness of desensitization protocols in gynecological cancer patients. Methods: Original, retrospective, descriptive, analytical study, approved by Bioethics and Research Committee, included >18-year-old patients with gynecological tumors experiencing HSRs to first-line chemotherapy. Patients underwent 3-bag-12-step desensitization. Results: 174 desensitization (95 paclitaxel, 79 carboplatin) in 33 female patients, mean age 45.5 years (18–71y). Cancer diagnosis: breast 8 (24.2%), ovarian 14 (42.2%), endometrial 2 (6.1%) and cervix 9 (27.2%). HSR occurred in paclitaxel during cycles 1–2 and in carboplatin after 6 cycles. The most frequently seen HSR symptom was cardiovascular with paclitaxel (94.7%), and cutaneous (93.3%) with carboplatin. Three-bags 12-steps desensitization protocol (initial dilution 1:100) in 5.67hrs. All patients reached total dose desensitization: 82% with no reaction, 12% mild, 6% moderate and 0% severe reaction. Mean disease-free interval and progression-free interval in months (m): breast cancer 29 m and 14 m, ovarian 22 m and 9 m, endometrial 40 m and cervical cancer: 67.5 m and 27 m. Twenty-five patients (73.5%) are still alive. Conclusion: HSRs to paclitaxel manifest in the first 1–2 cycles and to carboplatin after 6 cycles. Symptoms include cardiovascular, atypical neuromuscular and urticaria. Changing treatment lines impacts prognosis. Our study revealed that ovarian cancer patients undergoing desensitization protocols achieved longer progression-free intervals. All patients successfully reached total dose desensitization. This study provides evidence of the effectiveness and safety of desensitization and promising perspective for continuing first-line treatment with HSRs.
- 28 August 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (6) , 955-964
Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy
Introduction: Taxanes and platinum are first-line treatments in gynecological tumors with high rates of hypersensitivity reactions (HSRs), leading to discontinuation of treatment. Desensitization involves induction of temporary tolerance to previously sensitized medications. The aims of this study are to describe HSRs to paclitaxel and carboplatin and evaluate the safety and effectiveness of desensitization protocols in gynecological cancer patients. Methods: Original, retrospective, descriptive, analytical study, approved by Bioethics and Research Committee, included >18-year-old patients with gynecological tumors experiencing HSRs to first-line chemotherapy. Patients underwent 3-bag-12-step desensitization. Results: 174 desensitization (95 paclitaxel, 79 carboplatin) in 33 female patients, mean age 45.5 years (18–71y). Cancer diagnosis: breast 8 (24.2%), ovarian 14 (42.2%), endometrial 2 (6.1%) and cervix 9 (27.2%). HSR occurred in paclitaxel during cycles 1–2 and in carboplatin after 6 cycles. The most frequently seen HSR symptom was cardiovascular with paclitaxel (94.7%), and cutaneous (93.3%) with carboplatin. Three-bags 12-steps desensitization protocol (initial dilution 1:100) in 5.67hrs. All patients reached total dose desensitization: 82% with no reaction, 12% mild, 6% moderate and 0% severe reaction. Mean disease-free interval and progression-free interval in months (m): breast cancer 29 m and 14 m, ovarian 22 m and 9 m, endometrial 40 m and cervical cancer: 67.5 m and 27 m. Twenty-five patients (73.5%) are still alive. Conclusion: HSRs to paclitaxel manifest in the first 1–2 cycles and to carboplatin after 6 cycles. Symptoms include cardiovascular, atypical neuromuscular and urticaria. Changing treatment lines impacts prognosis. Our study revealed that ovarian cancer patients undergoing desensitization protocols achieved longer progression-free intervals. All patients successfully reached total dose desensitization. This study provides evidence of the effectiveness and safety of desensitization and promising perspective for continuing first-line treatment with HSRs.